A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Traumatic Neuralgia, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension.
JNJ-42160443 is an experimental (investigational) drug that is being tested to see if it may be useful in treating subjects with moderate to severe neuropathic (nerve) pain that is not adequately controlled with or without standard pain therapy. An investigational drug is one that is not approved by the U.S. Food and Drug Administration (FDA).
This study will compare the effects (both good and bad) of JNJ-42160443 to those of placebo. Placebo looks like JNJ-42160443 and is administered in the same way, but it contains no active drug.
JNJ-42160443 is an antibody produced by special technologies. Antibodies are proteins naturally produced by your body that serve multiple purposes including fighting infections or removing other foreign proteins.
JNJ-42160443 binds to and inactivates a protein in your body called Nerve Growth Factor. In animal and human studies, Nerve Growth Factor was shown to increase pain. Animal and human studies with other experimental drugs that reduced Nerve Growth Factor have shown that this may reduce pain; however, this does not necessarily mean that JNJ-42160443 will work for you.
The purpose of this research study is to test how safe, tolerable, and effective JNJ-42160443 is in reducing average pain intensity, when compared to placebo (no active drug).